Payment overview · 2025
General Payments
$222.97
11 reported records · 5 companies
Healthcare provider profile · identity verified
Amy Lynn Keffer, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SWEENY, TX · NPI 1467415133
Verified facts
What the public records show
CMS Open Payments records show Amy Lynn Keffer, MD received $222.97 in general payments during 2025 across 11 reported records.
AstraZeneca Pharmaceuticals LP accounted for 47.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $105.11 | 47.1% | 6 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $51.82 | 23.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.09 | 13.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.14 | 9.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $13.81 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $222.97 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $105.11 | 6 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $51.82 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.09 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.09 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $13.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 129 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 77 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
79 | 22 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
129 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 857 | 197 |
| Atorvastatin Calcium | Atorvastatin Calcium | 484 | 129 |
| Amlodipine Besylate | Amlodipine Besylate | 458 | 123 |
| Pantoprazole Sodium | Pantoprazole Sodium | 371 | 105 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 297 | 80 |
| Irbesartan | Irbesartan | 260 | 68 |
| Meloxicam | Meloxicam | 230 | 61 |
| Zolpidem Tartrate | Zolpidem Tartrate | 223 | 36 |
| Lisinopril | Lisinopril | 217 | 60 |
| Losartan Potassium | Losartan Potassium | 203 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 196 | 53 |
| Gabapentin | Gabapentin | 192 | 51 |
| Potassium Chloride | Potassium Chloride | 189 | 45 |
| Sertraline Hcl | Sertraline Hcl | 189 | 43 |
| Allopurinol | Allopurinol | 188 | 48 |
| Furosemide | Furosemide | 180 | 59 |
| Glimepiride | Glimepiride | 180 | 50 |
| Omeprazole | Omeprazole | 176 | 47 |
| Ezetimibe | Ezetimibe | 175 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 173 | 41 |
| Metformin Hcl | Metformin Hcl | 171 | 53 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 153 | 113 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 143 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 139 | 51 |
| Farxiga | Dapagliflozin Propanediol | 129 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 37 |
| Azithromycin | Azithromycin | 122 | 104 |
| Methylprednisolone | Methylprednisolone | 122 | 92 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 33 |
| Tramadol Hcl | Tramadol Hcl | 119 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 111 | 30 |
| Spironolactone | Spironolactone | 109 | 22 |
| Valsartan | Valsartan | 109 | 29 |
| Trazodone Hcl | Trazodone Hcl | 108 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 104 | 88 |
| Carvedilol | Carvedilol | 99 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 98 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 98 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 97 | 25 |
| Bupropion Xl | Bupropion Hcl | 94 | 21 |
| Montelukast Sodium | Montelukast Sodium | 93 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 25 |
| Januvia | Sitagliptin Phosphate | 83 | 18 |
| Alprazolam | Alprazolam | 82 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 19 |
| Synthroid | Levothyroxine Sodium | 79 | 22 |
| Ozempic | Semaglutide | 77 | 16 |
| Simvastatin | Simvastatin | 74 | 19 |
| Celecoxib | Celecoxib | 70 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 69 | 23 |
| Cefuroxime | Cefuroxime Axetil | 62 | 54 |
| Clonazepam | Clonazepam | 61 | 14 |
| Meclizine Hcl | Meclizine Hcl | 61 | 19 |
| Glipizide | Glipizide | 59 | 13 |
| Raloxifene Hcl | Raloxifene Hcl | 58 | 15 |
| Estradiol | Estradiol | 53 | 17 |
| Donepezil Hcl | Donepezil Hcl | 52 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 51 | 30 |
| Eliquis | Apixaban | 50 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 46 | 22 |
| Bumetanide | Bumetanide | 44 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 17 |
| Buspirone Hcl | Buspirone Hcl | 43 | 13 |
| Nifedipine Er | Nifedipine | 43 | 11 |
| Folic Acid | Folic Acid | 42 | suppressed |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | suppressed |
| Levofloxacin | Levofloxacin | 39 | 29 |
| Mupirocin | Mupirocin | 39 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 24 |
| Guanfacine Hcl | Guanfacine Hcl | 34 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 19 |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 18 |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Cefdinir | Cefdinir | 25 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Naproxen | Naproxen | 19 | 11 |
| Prednisone | Prednisone | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 17 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 16 | suppressed |
| Zaleplon | Zaleplon | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 13 | 12 |
| Diazepam | Diazepam | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 13 |
| Ramipril | Ramipril | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $222.97 · 11 records | AstraZeneca Pharmaceuticals LP | AUSTEDO XR, FARXIGA, Ozempic, QULIPTA, UBRELVY, Veozah | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error